AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD.

AB/FF led to significantly greater improvements in change from baseline in morning pre-dose (trough) FEV 1 vs FF (55 mL, P <0.001; co-primary endpoint); however, the improvements for AB/FF compared with AB (14 mL) and TIO (19 mL) did not reach statistical significance ( Figure 4 ).

also in 111,027 other papers